A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Recruiting

Phase 1

Phase 2

Ifinatamab DeruxtecanA Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

Sponsor:

Merck Sharp & Dohme LLC

Code:

NCT06863272

Conditions

Castration-Resistant Prostatic Cancer

Metastasis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Docetaxel

Ifinatamab Deruxtecan

MK-5684

Abiraterone

Enzalutamide

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-05. This information was provided to ClinicalTrials.gov by Merck Sharp & Dohme LLC on 2025-10-30.